INTRODUCTION

Doxorubicin (DOX), an anticancer drug used in chemotherapy, causes significant cardiotoxicity. This study aimed to investigate the effects of DOX on mouse cardiac electrophysiology, in conscious versus anesthetized state.

METHODS: Male and female C57BL/6 mice were injected with saline, 20 or 30 mg/kg DOX. ECGs were recorded 5 days post-injection in conscious and isoflurane anesthetized states. ECGs were analyzed using custom MATLAB software to determine P, PR, QRS, QTc, and RR intervals as well as heart rate variability (HRV).

RESULTS: ECGs from the same mouse demonstrated P wave and QTc shortening as well as PR and RR interval prolongation in anesthetized versus conscious saline-treated mice. ECG response to DOX was also modulated by anesthesia. DOX treatment induced significant ECG modulation in female mice alone. While DOX20 treatment caused decrease in P and QRS durations, DOX30 treatment-induced QTc and RR interval prolongation in anesthetized but not in conscious female mice. These data suggest significant sex differences and anesthesia-induced differences in ECG response to DOX. HRV measured in time and frequency domains, a metric of arrhythmia susceptibility, was increased in DOX20-treated mice compared to saline.

CONCLUSIONS: This study for the first time identifies that the ECG response to DOX is modulated by anesthesia. Furthermore, this response demonstrated stark sex differences. These findings could have significant implications in clinical diagnosis of DOX cardiotoxicity.

KEYWORDS: anesthesia, doxorubicin, electrocardiography, isoflurane, sex differences

1 | INTRODUCTION

Doxorubicin (DOX) is an anthracycline antibiotic that is used in anticancer chemotherapy to treat several types of cancers including breast cancer, leukemia, and lymphoma (Trachtenberg et al., 2011). While DOX is very efficient in anticancer therapy, it has well-established cardiotoxic effects and causes an increase in the development of fatal cardiotoxicity and heart failure (Chatterjee et al., 2010; Šimůnek et al., 2009; Swain et al., 2003).
DOX destroys cancer cells by inducing DNA fragmentation but it also has several detrimental side effects such as increased ROS production, inflammation, and antioxidant depletion which triggers the cellular stress signaling response (George et al., 2020; Ichikawa et al., 2014; Kim et al., 2006; Šimůnek et al., 2009). Several groups have identified the mechanistic pathways that are activated in this stress response to DOX and p38 MAPK activation and its role in promoting DOX cardiotoxicity is well established (Bernstein et al., 2005; George et al., 2020; Ma et al., 2012; Nozaki et al., 2004; Riad et al., 2008; Thandavarayan et al., 2010; Yi et al., 2007; Zhang et al., 2012). Activation of stress signaling pathways inhibits autophagy, increases apoptosis, fibrosis, cardiac dysfunction, and increases morbidity and mortality. Our group recently reported sex differences in the stress response to DOX treatment. Specifically, p38δ activation is associated with DOX-induced cardiotoxicity in female mice (George et al., 2020).

DOX also affects cardiac electrophysiology and DOX-induced changes in ion currents and action potentials have been previously reported (Fernandez-Chas et al., 2018; Milberg et al., 2007; Sag et al., 2011; Wang et al., 2001; Wang & Korth, 1995). DOX decreases the delayed rectifier potassium current (I_{K_d}) and increases the L-type calcium current (I_{CaL}) which results in action potential duration (APD) prolongation chronically, although DOX has been reported to acutely shorten APD (Fernandez-Chas et al., 2018; Milberg et al., 2007; Sag et al., 2011; Wang et al., 2001; Wang & Korth, 1995). DOX also alters calcium handling and increases leak from the sarcoplasmic reticulum (Sag et al., 2011).

Due to numerous detrimental effects of DOX on cardiac function, it is crucial to identify techniques for early diagnosis of cardiotoxicity. Currently, echocardiography is the method of choice in the clinical setting and ejection fraction is the preferred metric (Meijers & Moslehi, 2019; Perez et al., 2019). However, in our previous study, we demonstrated the role of preserved ejection fraction in some subjects as a potential cause of undiagnosed DOX-induced cardiotoxicity (George et al., 2020). Electrocardiography (ECG) is another method to detect DOX cardiotoxicity in patients, however, this technique too has its limitations. For example, the majority of ECGs recorded in a clinical setting are taken when the patient is in a conscious state. In contrast, most ECG recordings in animal models that were used to study and identify DOX cardiotoxicity were obtained from anesthetized mice. Anesthesia has also been shown to alter ECG parameters and decrease heart rate compared to conscious mice (Lindsey et al., 2018). Differences in physiological responses between conscious and anesthetized subjects and lack of robust correlation between studies in animal models to clinical testing, could complicate the diagnosis of acute cardiotoxicity in chemotherapy patients. This relationship, therefore, warrants a thorough investigation and is the objective of this study.

In this study, we determined the effects of DOX on cardiac electrophysiology and how it can be modulated by anesthesia. We report that DOX-induced changes in ECG are more prominent in the anesthetized versus conscious state. Furthermore, we identified that sex is a significant variable that further alters this response.

2 METHODS

All protocols were approved by the Institutional Animal Care and Use Committee of the George Washington University and were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

2.1 Mice

Male and female mice on a C57BL/6 background, were intra-peritoneally injected at ~15 weeks of age with either 20 mg/kg DOX (DOX20), 30 mg/kg DOX (DOX30), or saline (vehicle control) as shown in Figure 1A. Five days post-injection, ECGs were recorded from the mice in the conscious and anesthetized state.

In conscious mice, ECG was recorded at 1 kHz sampling rate using the emka Technologies ecgTUNNEL device. Mice were guided into a restraining tunnel and positioned in prone position in contact with four silver ECG electrodes. After a 5-minute acclimation period, conscious ECG recordings, approximately 2 min in duration, were recorded in lead I configuration (Figure 1B). Beyond 2 min, mice became stressed and motion artifacts were introduced into the signals. Mice were then anesthetized using isoflurane (1–2.5%, 1 ml/min oxygen) using an EZ anesthesia machine to maintain a heart rate of ~400 bpm (for echocardiography simultaneously performed and previously published (George et al., 2020)). Once unconscious, mice were transferred to the mouse platform of a Vevo 3100 ultrasound machine (FUJIFILM VisualSonics) and anesthesia administration was continued via a nose cone. A heated platform and heating lamp were used to maintain the body temperature of the mice during anesthesia. The limbs of the mice in supine position were taped to the four silver/silver chloride ECG electrodes on the platform and anesthetized.
ECG was recorded at a sampling rate of 8 kHz in lead II configuration (Figure 1C). Each file was of about 8 s in duration. ECG files were recorded along with the echocardiography files (data previously published (George et al., 2020)). Both conscious and anesthetized ECG traces were analyzed using the same custom MATLAB program and in the same manner as described below.

2.2 | Electrocardiography Analysis

Conscious and anesthetized ECG data were exported to txt and csv file formats, respectively, and ECG parameters were measured using a custom MATLAB program (George et al., 2020). P, PR, QRS, QT, and RR intervals/durations were measured as illustrated in Figure 1B,C and as previously described (Boukens et al., 2014). QTc interval was calculated as

$$QTc = \frac{QT}{\sqrt{RR/100}}$$

2.3 | Heart rate variability (HRV) analysis

Time and frequency domain HRV analysis were performed using a custom MATLAB program. Frequency domain HRV analysis was only performed on conscious mice because the anesthetized ECG recording was not of sufficient duration for this analysis.
2.3.1 | Time domain HRV analysis

A standard Poincaré plot was generated using consecutive RR intervals, RR
\(_n\) versus RR
\(_{n+1}\). SD1 and SD2 were measured as the short half axis and long half axis of an ellipse fitted to the Poincaré plot (Karmakar et al., 2009). SD1 represents short-term variability and was calculated as
\[ SD_1^2 = \frac{1}{2} SDSD^2, \]
where SDSD is the standard deviation of the successive difference of RR interval. SD2 represents the long-term variability and is calculated as
\[ SD_2^2 = 2SDRR^2 - \frac{1}{2} SDSD^2, \]
where SDRR is the standard deviation of RR interval (Karmakar et al., 2009; Shaffer & Ginsberg, 2017). SD1/SD2 ratio represents the autonomic balance.

2.3.2 | Frequency domain HRV analysis

Power spectral density (PSD) plot was created by plotting PSD against frequency. These measurements were once again calculated from the RR intervals. Power in the low- and high-frequency (LF and HF, respectively) bands were calculated by taking the integral of the PSD in the LF and HF ranges previously reported for mouse HRV calculation (Gehrmann et al., 2000; Thireau et al., 2007). LF represents sympathetic activity and the frequency range used for LF was 0.1–1.5 Hz. HF represents the parasympathetic activity and frequency range used to measure HF was 1.5–4 Hz, as previously described (Thireau et al., 2007; Zila et al., 2015). The ratio of LF/HF represents an index of parasympathetic–sympathetic (autonomic) balance (Hsu et al., 2012). LF/HF correlates with the SD1/SD2 ratio in time domain analysis (Hsu et al., 2012). Similarly, SD1 correlates with HF and SD2 is closely correlated with LF.

2.4 | Statistics

Statistical analyses were performed using GraphPad Prism software. All data are reported as mean ± standard deviation. Paired (conscious vs. anesthetized) and unpaired (Saline vs. DOX20/DOX30, males vs. females) Student's t tests were performed to determine statistical significance in differences between means and Bonferroni correction was applied to account for multiple comparisons. \( P < 0.05 \) denoted significance. Sample sizes for each data set are listed in the table and figure legends.

3 | RESULTS

3.1 | Isoflurane anesthesia modulates ECG

The effect of isoflurane anesthesia on ECG parameters in male and female mice was assessed with respect to conscious state of the same mice (Figure 2; Table 1). P wave duration, indicative of atrial excitation time, was shortened in male anesthetized versus conscious mice. On the other hand, PR interval, which denotes the atroioventricular (AV) delay, was prolonged in female anesthetized versus conscious mice but not in males. Interestingly, QRS duration, which indicates the ventricular excitation time, had opposite response in males and females. QRS duration was prolonged in female anesthetized versus conscious mice but shortened in male anesthetized versus conscious mice. QT interval was similar between the two states in males and females although RR interval prolongation in anesthetized mice resulted in shortened QTc intervals.

3.2 | DOX-induced ECG changes are modulated by anesthesia

ECG response in DOX-treated anesthetized and conscious mice was compared next and is illustrated/summarized in Figure 3 and Table 1. DOX and isoflurane anesthesia, individually and in combination, induced more changes in female ECGs compared to males. First, looking at the effects of DOX alone in conscious mice, DOX30 induced QRS and QT interval prolongation in female mice. No changes in ECG parameters were measured in male mice or those treated with DOX20. Next, in anesthetized mice, with the combination of DOX and isoflurane, DOX20 shortened P and QRS durations while DOX30 treatment prolonged QT, QTc, and RR intervals in females. Once again, DOX did not alter any ECG parameters in anesthetized males.

Lastly, we compared ECG parameters between conscious and anesthetized mice within the same treatment group (DOX20 and DOX30). In DOX20-treated mice, isoflurane anesthesia caused P wave and QTc interval shortening, and PR and RR interval prolongation among females, while in males PR and RR interval prolongation was observed. Similar effects were observed with DOX30 treatment. Additionally, anesthesia prolonged the QT interval in female DOX30-treated mice, and QRS duration in males.

To summarize, DOX induced the most significant changes in ECG parameters in female anesthetized mice compared to all other groups studied here. This indicates that there are differences in ECG response between the conscious and anesthetized states, males and females, during DOX treatment.

3.3 | Sex differences in ECG response to DOX

Sex differences in response to DOX were investigated next. ECG parameters in DOX30-treated mice were normalized to its own saline control (Figure 4). First, when comparing
between the anesthetized and conscious mice within the same sex, QT and QTc intervals were significantly prolonged in anesthetized versus conscious females, while no significant differences were measured in males.

Sex differences in ECG response to DOX were also observed. QTc interval was significantly prolonged in anesthetized females compared to males. A similar trend is also observed in QT interval, however, the presence of three
very sick mice in the anesthetized male group appears to limit the statistical significance of this metric. Taken together, these results further demonstrate that DOX-induced ECG modulation is more pronounced in female mice than in males.

### 3.4 | Time domain HRV analysis

HRV was next measured from Poincaré plots as illustrated in Figure 5. There is little dispersion in beat-to-beat RR intervals in anesthetized mice, which indicates very little HRV even after DOX treatment (Figure 5A, Left). On the other hand, there is more dispersion in the conscious Poincaré plots (Figure 5A, Right), especially when the mice were treated with DOX. SD1 and SD2 were significantly increased in conscious versus anesthetized female mice treated with DOX20. Additionally, comparing DOX to saline-treated mice, DOX20 treatment further increased SD2 in conscious female mice which in turn decreased the SD1/SD2 ratio. No significant changes in the time domain HRV parameters were measured in males.

### TABLE 1  Summary of data

| Anesthetized mice | Female | | Male | | |
|-------------------|--------|--------|--------|--------|--------|
|                   | Saline | DOX 20 | DOX 30 | Saline | DOX 20 | DOX 30 |
| P (ms)            | 15.2 ± 1.5 | 11.2 ± 1.2** | 11.6 ± 2.8 | 11.4 ± 1.4 | 11.6 ± 0.8 | 15.5 ± 7.2 |
| PR (ms)           | 62.2 ± 9.1 | 58.7 ± 4.8 | 57.0 ± 7.0 | 51.9 ± 7.5 | 50.5 ± 4.1 | 63.7 ± 20.0 |
| QRS (ms)          | 15.3 ± 0.6 | 13.1 ± 0.9** | 17.5 ± 4.9 | 12.4 ± 0.7 | 12.8 ± 2.5 | 14.4 ± 3.2 |
| QT (ms)           | 40.0 ± 2.1 | 38.6 ± 12.6 | 82.8 ± 11.2** | 43.7 ± 6.3 | 54.5 ± 11.4 | 73.3 ± 35.9 |
| QTc (ms)          | 34.1 ± 1.5 | 33.4 ± 10.9 | 60.3 ± 5.9** | 36.0 ± 3.7 | 46.1 ± 8.4 | 46.5 ± 15.6 |
| RR (ms)           | 136.5 ± 5.4 | 138.2 ± 11.8 | 187.2 ± 24.3** | 144.0 ± 14.1 | 136.3 ± 16.2 | 218.5 ± 77.1 |
| SD1 (ms)          | 0.8 ± 0.5 | 1.3 ± 1.1 | 2.1 ± 3.8 | 0.7 ± 0.3 | 4.8 ± 10.4 | 4.9 ± 4.9 |
| SD2 (ms)          | 1.0 ± 0.7 | 1.3 ± 0.7 | 2.7 ± 5.9 | 0.9 ± 0.5 | 4.7 ± 9.8 | 5.4 ± 4.9 |
| SD1/SD2           | 0.8 ± 0.1 | 0.9 ± 0.3 | 1.2 ± 0.8 | 0.9 ± 0.4 | 1.0 ± 0.3 | 0.9 ± 0.3 |

| Conscious mice | Female | | Male | | |
|----------------|--------|--------|--------|--------|--------|
|                   | Saline | DOX 20 | DOX 30 | Saline | DOX 20 | DOX 30 |
| P (ms)            | 17.5 ± 1.6 | 18.5 ± 3.8* | 15.7 ± 3.0 | 19.8 ± 2.3* | 15.8 ± 4.5 | 18.2 ± 3.2 |
| PR (ms)           | 44.9 ± 3.6* | 41.1 ± 3.6** | 42.8 ± 4.6* | 43.8 ± 4.0 | 39.7 ± 3.2** | 49.9 ± 11.5 |
| QRS (ms)          | 13.6 ± 1.0* | 14.0 ± 1.0 | 16.6 ± 1.9** | 15.7 ± 1.8* | 13.6 ± 1.1 | 17.6 ± 4.2* |
| QT (ms)           | 43.2 ± 2.8 | 45.4 ± 3.0 | 50.7 ± 1.4*** | 42.1 ± 3.0 | 45.8 ± 3.5 | 52.4 ± 9.4 |
| QTc (ms)          | 43.6 ± 3.8* | 45.5 ± 3.8* | 46.4 ± 3.4 | 43.6 ± 1.9* | 46.2 ± 2.6 | 46.3 ± 4.0 |
| RR (ms)           | 99.6 ± 14.3* | 101.1 ± 14.8* | 122.2 ± 18.2* | 93.2 ± 7.3* | 99.8 ± 20.4* | 134.0 ± 50.2* |
| SD1 (ms)          | 14.3 ± 6.5 | 25.6 ± 8.1* | 5.7 ± 4.9 | 8.9 ± 5.0 | 15.2 ± 7.6 | 13.7 ± 8.2 |
| SD2 (ms)          | 17.9 ± 8.6 | 38.9 ± 14.5** | 6.7 ± 5.7 | 15.9 ± 9.6 | 19.9 ± 10.9 | 18.8 ± 11.0 |
| SD1/SD2           | 0.8 ± 0.1 | 0.7 ± 0.1* | 0.9 ± 0.3 | 0.6 ± 0.2 | 0.8 ± 0.3 | 0.7 ± 0.2 |
| LF (ms²)          | 1.8 ± 1.3 | 7.8 ± 6.0 | 1.0 ± 2.2 | 1.2 ± 1.3 | 3.0 ± 2.6 | 12.7 ± 23.7 |
| HF (ms²)          | 2.8 ± 2.2 | 5.0 ± 4.1 | 2.1 ± 4.8 | 0.8 ± 1.0 | 2.5 ± 1.9 | 10.3 ± 20.1 |
| LF/HF             | 0.7 ± 0.2 | 1.7 ± 0.9 | 0.3 ± 0.2** | 2.2 ± 1.4 | 2.2 ± 2.6 | 1.5 ± 0.8 |

The mean ± standard deviation of all ECG and HRV parameters from each experimental group is listed. The data sets are separated by anesthetized versus conscious, sex, and then by treatment (saline, DOX20, or DOX30).

Abbreviations: HF, High-frequency HRV; LF, Low-frequency HRV; LF/HF, Ratio of low- and high-frequency HRV; P, P wave duration; PR, PR interval; QRS, QRS duration; QT, QT interval; QTc, QTc interval; RR, RR Interval; SD1, Standard deviation of short-term HRV; SD1/SD2, Ratio of short- and long-term HRV; SD2, Standard deviation of long-term HRV.

Sample sizes for each group are as follows: Females—Conscious Saline: n = 6, Conscious DOX20: n = 10, Conscious DOX30: n = 7, Anesthetized Saline: n = 6, Anesthetized DOX20: n = 10, Anesthetized DOX30: n = 10 and Males—Conscious Saline: n = 6, Conscious DOX20: n = 8, Conscious DOX30: n = 8, Anesthetized Saline: n = 6, Anesthetized DOX20: n = 8, Anesthetized DOX30: n = 8.

*indicates p < 0.05 versus anesthetized mice (paired). **indicates p < 0.05 versus saline-treated group (unpaired).
To summarize, while DOX-induced changes in the ECG parameters discussed above are more prominent in the anesthetized mice, DOX-induced changes in HRV are more prominent in conscious mice. However, in both instances, female mice displayed more pronounced cardiotoxic ECG response compared to males.

3.5 | Frequency domain HRV analysis

Frequency domain HRV analysis was performed only on conscious mice ECG due to the limited duration of anesthetized mice ECG. DOX20 treatment in female mice increased LF and HF compared to saline (Figure 6), although it was not significant due to the larger variability in these parameters.

Of note, two clusters of LF values were observed in DOX20-treated females suggesting two different responses to DOX treatment. On the other hand, DOX30 treatment did not alter LF or HF parameters in males or females even though LF/HF ratio was significantly reduced in females. This reduction was due to a non-significant reduction in LF, suggesting reduced sympathetic tone in these mice.

4 | DISCUSSION

In this study, the role of isoflurane anesthesia in modulating ECG response to DOX treatment was investigated in male and female mice. We report here that isoflurane by itself modulates ECG parameters and furthermore, also alters ECG
response to DOX treatment in a sex-dependent manner. ECG modulation in response to DOX treatment was most significant in female anesthetized mice. Time and frequency domain HRV analyses indicated increased HRV in conscious compared to anesthetized mice, with DOX treatment further increasing HRV. These findings uncover a significant variable that can confound the translation of basic cardiotoxicity research, primarily performed in anesthetized laboratory animals, to clinical acute and chronic cardiotoxicity studies performed in conscious patients. Additionally, it highlights the importance of taking into consideration sex differences in determining cardiotoxic ECG response in laboratory and clinical settings.

4.1 Effects of isoflurane on ECG:

Isoflurane is a commonly used anesthetic in mice because it is stable, has a short induction time, and has no long-term effects on mice (Lindsey et al., 2018; Ludders, 1992). Isoflurane anesthesia has several direct and indirect (via modulating autonomic tone) effects on cardiac physiology. It is well established that isoflurane slows heart rate and, therefore, prolongs RR interval in ECGs (Constantinides et al., 2011; Lindsey et al., 2018). Consistent with previous studies, we observed prolonged RR intervals in male and female anesthetized mice relative to conscious mice. We additionally report here that isoflurane anesthesia modulated P wave duration, PR interval, QRS duration, and QTc interval.

P wave duration is indicative of the time taken for atrial excitation, and PR interval denotes the time taken for electrical excitation to propagate from the atria to the ventricles via the AV node. P wave duration shortening in male mice observed in this study suggests faster electrical excitation propagation in the atria of anesthetized mice. On the other hand, prolonged PR interval in anesthetized females could suggest increased AV delay in these mice during isoflurane anesthesia.

QRS duration represents the ventricular excitation time. Interestingly, we observed opposite effects of isoflurane anesthesia on QRS duration in male and female mice. While isoflurane prolonged QRS duration in female mice, it shortened QRS duration in male mice. Factors that can contribute to such acute changes in ventricular excitation could include ion channel function modulation, particularly the depolarizing sodium current. Isoflurane has been reported to inhibit the fast sodium current which could result in QRS prolongation as observed in the female mice in this study (Weigt et al., 1997). However, sex differences in the effects of isoflurane on INa have not been reported and the basis for QRS shortening in male mice will require further investigation.

Isoflurane alters multiple cardiac ion currents and can also alter APD (Hüneke et al., 2004). Isoflurane inhibits T- and L-type calcium currents which can shorten APD (Hüneke et al.,
FIGURE 5 Time Domain HRV Analysis. (a) Poincaré plots for anesthetized (left, filled circles) and conscious (right, open circles) mice show heart rate variability in saline (black), DOX20 (red), and DOX30 (blue)-treated mice. (b) SD1, SD2, and SD1/SD2 ratios are reported for each group. Statistics: Paired and unpaired Student's t test with Bonferroni correction were performed to determine statistical significance between groups. *indicates $p < 0.05$ versus anesthetized mice (paired) and #indicates $p < 0.05$ versus saline-treated group (unpaired). Sample sizes for each group are as follows: Females—Conscious Saline: $n = 6$, Conscious DOX20: $n = 10$, Conscious DOX30: $n = 10$, Anesthetized Saline: $n = 6$, Anesthetized DOX20: $n = 9$, Anesthetized DOX30: $n = 7$ and Males—Conscious Saline: $n = 6$, Conscious DOX20: $n = 8$, Conscious DOX30: $n = 8$, Anesthetized Saline: $n = 6$, Anesthetized DOX20: $n = 8$, Anesthetized DOX30: $n = 6$

DOX administration (a dose of 3.75 mg/kg at week 2, 3, 4, and 5 to make a cumulative dose of 15 mg/kg) has also been reported to decrease heart rate (Hazari et al., 2009). Consistent with these findings, we report here that DOX30 treatment prolonged QT and QTc intervals and reduced heart rate (increased RR interval) in anesthetized mice, however, these effects were only observed in female mice and not in males. In contrast to previous studies, we report here that DOX treatment resulted in significantly shortened QRS duration in females due to species-specific differences (rats vs. mice) or due to the additional effect of the anesthetic used (mild ether anesthetic vs. isoflurane). Finally, we also observed P duration shortening after DOX treatment, once again, only in female anesthetized mice. Thus, to summarize, in anesthetized female mice, acute effects of DOX include faster conduction of electrical impulses in the atria and ventricles (short P and QRS), prolonged repolarization (QT), and slowed heart rate.

Previous studies that performed conscious ECG recordings in rats, report DOX-induced prolongation of PR interval, QRS duration, QTc interval, and ST interval (Hazari et al., 2009; Jensen et al., 1984). Consistent with these studies, we also observed QRS and QT prolongation in female conscious mice. Interestingly, the effect of DOX on QRS duration in female mice was opposing in conscious versus anesthetized states in the present study. While QRS duration was shortened by DOX in female anesthetized mice, it was prolonged in conscious state. This is the first study to directly compare the effects of DOX on male and female ECGs. These sex- and anesthesia-induced differences could have a significant impact on acute cardiotoxicity diagnosis in the clinical setting. Finally, a dose-dependent HRV response was observed in DOX-treated mice where DOX20 increased HRV parameters, whereas DOX30 had similar HRV parameters compared to saline-treated mice. This biphasic response could be a result of reduced variability but more drastically modulated ECG parameters in the much sicker DOX30-treated mice.

4.3 Sex differences in ECG response to DOX

Previous human studies have demonstrated that there are sex differences in the recording of electrical activities in the heart.
(Meiners et al., 2018; Mieszczena et al., 2008; Ravens, 2018). These studies show prolonged PR interval and QRS duration and shortened QT interval in males compared to females. These studies also indicated slower heart rate in males compared to females.

Our present study for the first time identifies sex differences in ECG of anesthetized and conscious mice. While anesthesia in DOX30-treated female mice unmasked multiple ECG parameter modulations, no changes were observed in males. Interestingly, we demonstrated in our previous study (George et al., 2020) that cardiac dysfunction was more prevalent in DOX30-treated males compared to females. Thus, examining DOX treatment in mice uncovered sexual dimorphism in the ensuing cardiotoxicity and showed that cardiac electrical and mechanical functions were differently affected in males versus females.

Previous clinical studies have also identified that male sex is associated with increased risk of cardiotoxicity in adults (Meiners et al., 2018; Myrehaug et al., 2008, 2010). Mouse studies have also reported increased mortality among males treated with DOX compared to females (George et al., 2020; Meiners et al., 2018; Moulin et al., 2015). In contrast to these findings, we report here the acute modulation of more ECG parameters in female mice compared to males treated with DOX20 and DOX30. This sexual dimorphism in ECG response to DOX is a significant new finding that will impact the diagnosis of cardiotoxicity in patients. Separate measures of acute ECG responses to DOX treatment will need to be considered for the diagnosis of cardiotoxicity in patients.

4.4 | Clinical Implications

The findings of this study indicate that the state of consciousness of the subject can alter diagnostic parameters of DOX cardiotoxicity. More specifically, anesthesia unmasked acute ECG cardiotoxic response in DOX-treated female mice. Note that this does not warrant anesthetizing patients undergoing chemotherapy, and we caution against it. However, these findings have several important clinical implications. First, they suggest that a lack of cardiotoxic ECG response to DOX treatment in conscious patients may not correspond to a lack of cardiotoxicity. Cardiotoxic response may be more evident during a state of unconsciousness such as during sleep. Therefore, continuous monitoring of patients undergoing chemotherapy may be more suitable to identify acute cardiotoxicity. Second, while DOX cardiotoxicity is more prevalent in adult males (mice and humans) versus females (George et al., 2020; Meiners et al., 2018; Myrehaug et al., 2008, 2010), the findings presented here suggest that this may not be associated with significant ECG changes acutely. On the other hand, significant ECG changes were observed in female mice which exhibited lesser cardiac dysfunction and greater survival. This suggests that cardiotoxicity takes different forms between the sexes and diagnostic approaches must take these sex differences into account. Finally, these findings also highlight the lack of robust correlation between basic science research models and clinical data and underscore the need to identify and utilize models that more comprehensively mimic clinical conditions (in this case, anesthetized vs. conscious state).

4.5 | Limitations

This study employs a single dose, intraperitoneal injection of saline, DOX20, or DOX30, 5 days prior to the conscious and anesthetized ECG recording. While this is a well-established model for studying DOX cardiotoxicity in mice it is not representative of clinical chemotherapy regimens (George et al., 2020). Future studies will implement multiple smaller doses of DOX injections to study chronic cardiotoxicity manifestation in the ECG.

While we recorded ECGs in lead II configuration from anesthetized mice, lead I configuration was implemented for conscious mice due to differences in the devices used to record ECGs. This difference in ECG configurations can affect the morphology and some measurements of ECG parameters measured here. A previous study reported ~7 ms difference in QT intervals of patients measured from the two ECG leads (Salvi et al., 2012). However, this relatively small lead-based difference is unlikely to change the larger anesthesia- and DOX-induced ECG modulation reported in this study. Nonetheless, it is important to identify the difference in other ECG parameter measurements.

The study also recorded shorter ECG traces in the anesthetized mice compared to the recordings of conscious mice due to differences in the devices used. As a result, it was not possible to perform frequency domain HRV analysis on the anesthetized ECGs. There was not enough data to accurately estimate the low-frequency ranges and power spectra from an anesthetized mouse ECG recording which was about 8 s in length.

Finally, isoflurane by itself can modulate ECG as shown in Figure 1. Isoflurane can exert these effects on cardiac...
electrophysiology directly or indirectly by altering physiologic functions such as the autonomic balance. While this study simply attributes the observed ECG modulation to the state of anesthesia, future studies aimed at distinguishing between the mechanisms underlying isoflurane anesthesia, particularly in the presence of DOX, are crucial.

5 | CONCLUSIONS

We demonstrated here the independent and interdependent effects of (1) isoflurane anesthesia, (2) DOX treatment, and (3) sex in modulating mouse cardiac electrophysiology. While the heart rate slowing effect of isoflurane anesthesia is well-known, we have performed a thorough characterization of the mouse ECG response to isoflurane. We additionally identified that anesthesia can unmask the effects of DOX treatment on the ECG. This could have important implications in the diagnosis and treatment of DOX-induced cardiotoxic effects in the clinical setting. This finding is all the more significant because ECG collected from mice and other animal models in laboratory settings are mostly collected under anesthesia, while ECG acquisition in the clinical setting is performed in conscious patients. This could lead to masking of the ECG alterations to DOX treatment in these conscious patients, and highlight a lack of synchrony in basic science versus clinical research. Therefore, it is crucial to take into account conscious versus anesthetized state of the subjects in ECG studies.

AUTHOR CONTRIBUTIONS

SAG, TE, and IRE conceptualized and designed the study. SAG and SNO performed the experiments, AW, SAG, and SNO analyzed the data, AW and SAG prepared the manuscript, all authors edited and approved the manuscript.

ORCID

Sharon A. George https://orcid.org/0000-0001-9003-1158
Tatiana Efimova https://orcid.org/0000-0002-9869-1545

REFERENCES

Bernstein, D., Fajardo, G., Zhao, M., Urashima, T., Powers, J., Berry, G., & Kobilka, B. K. (2005). Differential cardioprotective/cardiotoxic effects mediated by β-adrenergic receptor subtypes. American Journal of Physiology-Heart and Circulatory Physiology, 289, H2441–H2449. https://doi.org/10.1152/ajpheart.00005.2005

Boukens, B. J., Rivaud, M. R., Rentschler, S., & Coronel, R. (2014). Misinterpretation of the mouse ECG: “Musing the waves of Mus musculus”. Journal of Physiology, 592, 4613–4626. https://doi.org/10.1113/jphysiol.2014.279380

Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010). Doxorubicin cardiomyopathy. Cardiology, 115, 115–162. https://doi.org/10.1159/000265166

Constantinides, C., Mean, R., & Janssen, B. J. (2011). Effects of isoflurane anesthesia on the cardiovascular function of the C57BL/6 mouse. ILAR Journal, 52, e21–e31.

Fernandez-Chas, M., Curtis, M. J., & Niederer, S. A. (2018). Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model. British Journal of Pharmacology, 175, 763–781. https://doi.org/10.1111/bph.14104

Gehrman, J., Hammer, P., Maguire, C., Wakimoto, H., Triedman, J., & Berul, C. (2000). Phenotypic screening for heart rate variability in the mouse. American Journal of Physiology-Heart and Circulatory Physiology, 279, H7330–H7740. https://doi.org/10.1152/ajpheart.2000.279.2.H733

George, S., Kiss, A., Obaid, S., Venegas, A., Talapatra, T., Wei, C., Efimova, T., & Efimov, I. R. (2020). p38δ genetic ablation protects female mice from anthracycline cardiotoxicity. American Journal of Physiology. Heart and Circulatory Physiology, 319, H775–H786. https://doi.org/10.1152/ajpheart.00415.2020

Hazari, M. S., Haykal-Coates, N., Winsett, D. W., Costa, D. L., & Farraj, A. K. (2009). Continuous electrocardiogram reveals differences in the short-term cardiotoxic response of Wistar-Kyoto and spontaneously hypertensive rats to doxorubicin. Toxicological Sciences, 110, 224–234. https://doi.org/10.1093/toxsci/kfp092

Hsu, C. H., Tsai, M. Y., Huang, G. S., Lin, T. C., Chen, K. P., Ho, S. T., Shyu, L. Y., & Li, C. Y. (2012). Poincaré plot indexes of heart rate variability detect dynamic autonomic modulation during general anesthesia induction. Acta Anaesthesiologica Taiwanica, 50, 12–18. https://doi.org/10.1016/j.aat.2012.03.002

Hüneke, R., Faßl, J., Rossaint, R., & Lückhoff, A. (2004). Effects of volatile anesthetics on cardiac ion channels. Acta Anaesthesiologica Scandinavica, 48(5), 547–561. https://doi.org/10.1111/j.0001-5172.2004.00391.x

Hüneke, R., Jüngling, E., Skasa, M., Rossaint, R., & Lückhoff, A. (2001). Effects of the anesthetic gases xenon, halothane, and isoflurane on calcium and potassium currents in human atrial cardiomyocytes. Anesthesiology, 95, 999–1006. https://doi.org/10.1097/00000542-200110000-00032

Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Naga Prasad, S. V., Mutharasan, R. K., Jain Raik, T., & Ardehali, H. (2014). Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. Journal of Clinical Investigation, 124, 617–630. https://doi.org/10.1172/JCI72931

Jensen, R. A., Acton, E. M., & Peters, J. H. (1984). Doxorubicin cardiotoxicity in the rat: Comparison of electrocardiogram, transmembrane potential, and structural effects. Journal of Cardiovascular Pharmacology, 6, 186–200.

Karmakar, C. K., Khandoker, A. H., Gabbi, J., & Palaniswami, M. (2009). Complex correlation measure: a novel descriptor for Poincaré plot. BioMedical Engineering OnLine, 8, 17. https://doi.org/10.1186/1475-925X-8-17

Kim, S. Y., Kim, S. J., Kim, B. J., Rah, S. Y., Sung, M. C., Im, M. J., & Kim, U. H. (2006). Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Experimental & Molecular Medicine, 38, 535–545. https://doi.org/10.1038/emm.2006.63

Lindsey, M. L., Kassiri, Z., Virag, J. A. I., De Castro Brás, L. E., & Scherrer-Crosbie, M. (2018). Guidelines for measuring cardiac physiology in mice. American Journal of Physiology-Heart and Circulatory Physiology, 314(4), H733–H752. https://doi.org/10.1152/ajpheart.00339.2017
Ludders, J. W. (1992). Advantages and guidelines for using isoflurane. *Veterinary Clinics of North America - Small Animal Practice, 22*, 328–331. https://doi.org/10.1016/s0195-5616(92)50626-x

Ma, Y., Zhang, X., Bao, H., Mi, S., Cai, W., Yan, H., Wang, Q., Wang, Z., Yan, J., Fan, G., Lindsey, M. L., & Hu, Z. (2012). Toll-like receptor (tlr) 2 and tlr4 differentially regulate doxorubicin-induced cardiomyopathy in mice. *PLoS One, 7*, e40763. https://doi.org/10.1371/journal.pone.0040763

Meijers, W. C., & Moslehi, J. J. (2019). Need for multidisciplinary research and data-driven guidelines for the cardiovascular care of patients with cancer. *JAMA - the Journal of the American Medical Association, 322*, 1775–1776. https://doi.org/10.1001/jama.2019.17415

Meiners, B., Shenoy, C., & Zordoky, B. N. (2018). Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity. *Bi nology of Sex Differences, 9*, 38. https://doi.org/10.1186/s13293-018-0198-2

Mieszczanska, H., Pietrasik, G., Piotrowicz, K., McNitt, S., Moss, A. J., & Zareba, W. (2008). Gender-related differences in electrocardiographic parameters and their association with cardiac events in patients after myocardial infarction. *American Journal of Cardiology, 101*, 20–24. https://doi.org/10.1016/j.amjcard.2007.07.077

Milberg, P., Fleischer, D., Stymphann, J., Osada, N., Mönig, G., Engelen, M. A., Bruch, C., Breithardt, G., Haverkamp, W., & Eckardt, L. (2007). Reduced repolarization reserve due to anthracycline therapy facilitates torsade de pointes induced by IKr blockers. *Basic Research in Cardiology, 102*, 42–51. https://doi.org/10.1007/s00395-006-0699-0

Moulin, M., Picque rau, J., Mateo, P., Fortin, D., Rucker-Martin, C., Gressette, M., Lefebvre, F., Gresikova, M., Solgadi, A., Veksl er, V., Garnier, A., & Ventura-Clapier, R. (2015). Sexual dimorphism of doxorubicin-mediated cardiotoxicity potential role of energy metabolism remodeling. *Circulation: Heart Failure, 8*, 98–108. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001180

Mulla, W., Gillis, R., Murninkas, M., Klapper-Goldstein, H., Gabay, H., Mor, M., Elyagon, S., Liel-Cohen, N., Bernus, O., & Etzion, Y. (2018). Unanesthetized rodents demonstrate insensitivity of QT interval and ventricular refractory period to pacing cycle length. *Frontiers in Physiology, 9*, 897. https://doi.org/10.3389/fphys.2018.00897

Myrehaug, S., Pintilie, M., Tsang, R., Mackenzie, R., Crump, M., Chen, Z., Sun, A., & Hodgson, D. C. (2008). Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy. *Leukemia & Lymphoma, 49*, 1486–1493. https://doi.org/10.1080/1042819080 2140873

Myrehaug, S., Pintilie, M., Yun, L., Crump, M., Tsang, R. W., Meyer, R. M., Sussman, J., Yu, E., & Hodgson, D. C. (2010). A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. *Blood, 116*, 2237–2240. https://doi.org/10.1016/blood-2010-01-263764

Nozaki, N., Shishido, T., Takeishi, Y., & Kubota, I. (2004). Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. *Circulation, 110*, 2869–2874. https://doi. org/10.1161/01.CIR.0000146889.46519.27

Orestes, P., Bojadzic, D., Chow, R. M., & Todorovic, S. M. (2009). Mechanisms and functional significance of inhibition of neuronal T-Type calcium channels by isoflurane. *Molecular Pharmacology, 75*, 542–554. https://doi.org/10.1124/mol.108.051664

Perez, I. E., Taveras Alam, S., Hernandez, G. A., & Sancassiani, R. (2019). Cancer therapy-related cardiac dysfunction: an overview for the clinician. *Clinical Medicine Insights: Cardiology, 13*, 1–11. https://doi.org/10.1177/1179546819866445

Ravens, U. (2018). Sex differences in cardiac electrophysiology. *Canadian Journal of Physiology and Pharmacology, 96*, 985–990. https://doi.org/10.1139/cjpp-2018-0179

Riad, A., Bien, S., Gratz, M., Escher, F., Westermann, D., Heimesaat, M. M., Bereswill, S., Krieg, T., Felix, S. B., Schultheiss, H. P., Kroemer, H. K., & Tschope, C. (2008). Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. *European Journal of Heart Failure, 10*, 233–243. https://doi.org/10.1016/j.ejhef.2008.01.004

Roussel, J., Champeroux, P., Roy, J., Richard, S., Fauconnier, J., Le Guennec, J., & Thireau, J. (2016). The complex QT/RR relationship in mice. *Scientific Reports*, 6, 25388. https://doi.org/10.1038/srep25388

Sag, C. M., Köhler, A. C., Anderson, M. E., Backs, J., & Maier, L. S. (2011). CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. *Journal of Molecular and Cellular Cardiology, 51*, 749–759. https://doi.org/10.1016/j.yjmcc.2011.07.016

Salvi, V., Karnad, D., Kerkar, V., Panicker, G., Manohar, D., Natekar, M., Kothari, S., Narula, D., & Lokhandwala, Y. (2012). Choice of an alternative lead for QT interval measurement in serial ECGs when Lead II is not suitable for analysis. *Indian Heart Journal, 64*, 535–540. https://doi.org/10.1016/j.ihj.2012.07.023

Shaffer, F., & Ginsberg, J. P. (2017). An overview of heart rate variability metrics and norms. *Frontiers in Public Health, 5*, 258. https://doi.org/10.3389/fpubh.2017.00258

Šimůnek, T., Štěrba, M., Popelová, O., Adamcová, M., Hrdina, R., & Geršl, V. (2009). Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. *Pharmacological Reports, 61*, 154–171. https://doi.org/10.1016/s1734-1140(09)70018-0

Speirschneider, T., & Thomsen, M. (2013). Physiology and analysis of the electrocardiographic T wave in mice. *Acta Physiologica, 209*, 262–271. Published online 2013 October 24. https://doi.org/10.1111/apha.12172

Suzuki, A., Bosnjak, Z. J., & Kwok, W. M. (2003). The effects of isoflurane on the cardiac slowly activating delayed rectifier potassium channel in guinea pig ventricular myocytes. *Anesthesia and Analgesia, 96*, 1308–1315. https://doi.org/10.1213/ane.00000000000057604.56578.77

Swain, S. M., Whaley, F. S., & Ever, M. S. (2003). Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. *Cancer, 97*, 2869–2879. https://doi.org/10.1002/cncr.14407

Thandavarayan, R. A., Watanabe, K., Sari, F. R., Ma, M., Lakshmanan, A. P., Giridharan, V. V., Gurusamy, N., Nishida, H., Konishi, T., Zhang, S., Muslin, A. J., Kodama, M., Lakshmanan, A. P., Giridharan, V. V., Gurusamy, N., Nishida, H., Konishi, T., Zhang, S., Muslin, A. J., Kodama, M., & Aizawa, Y. (2010). Modulation of doxorubicin-induced cardiac dysfunction in dominant-negative p38α mitogen-activated protein kinase mice. *Free Radical Biology and Medicine, 49*, 1422–1431. https://doi.org/10.1016/j.freeradbiomed.2010.08.005

Thireau, J., Zhang, B. L., Poisson, D., & Babuty, D. (2007). Heart rate variability in mice: A theoretical and practical guide. *Experimental Physiology, 92*, 83–94. https://doi.org/10.1113/expphysiol.2007.040733
Trachtenberg, B. H., Landy, D. C., Franco, V. I., Henkel, J. M., Pearson, E. J., Miller, T. L., & Lipshultz, S. E. (2011). Anthracycline-associated cardiotoxicity in survivors of childhood cancer. *Pediatric Cardiology*, 94, 525:33. https://doi.org/10.1136/hrt.2007.136093

Wang, G. X., Wang, Y. X., Zhou, X. B., & Korth, M. (2001). Effects of doxorubicinol on excitation-contraction coupling in guinea pig ventricular myocytes. *European Journal of Pharmacology*, 423, 99–107. https://doi.org/10.1016/s0014-2999(01)01096-2

Wang, Y. X., & Korth, M. (1995). Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium. *Circulation Research*, 76, 645–653. https://doi.org/10.1161/01.res.76.4.645

Weigt, H. U., Kwok, W. M., Rehmert, G. C., Turner, L. A., & Bosnjak, Z. J. (1997). Voltage-dependent effects of volatile anesthetics on cardiac sodium current. *Anesthesia and Analgesia*, 84, 285–293. https://doi.org/10.1097/00000539-199702000-00009

Yi, L. L., Kerrigan, J. E., Lin, C. P., Azarova, A. M., Tsai, Y. C., Ban, Y., & Liu, L. F. (2007). Topoisomerase IIβ-mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. *Cancer Research*, 67, 8839–8846. https://doi.org/10.1158/0008-5472.CAN-07-1649

Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L. S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012). Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nature Medicine*, 18, 1639–1642. https://doi.org/10.1038/nm.2919

Zila, I., Mokra, D., Kopincova, J., Kolomaznik, M., Javorka, M., & Calkovska, A. (2015). Heart rate variability and inflammatory response in rats with lipopolysaccharide-induced endotoxemia. *Physiological Research*, 64, S669–S676. https://doi.org/10.33549/physiolres.933226

How to cite this article: Warhol, A., George, S. A., Obaid, S. N., Efimova, T., & Efimov, I. R. (2021). Differential cardiotoxic electrocardiographic response to doxorubicin treatment in conscious versus anesthetized mice. *Physiological Reports*, 9, e14987. https://doi.org/10.14814/phy2.14987